Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Regeneration of Injured Gluteal Musculature (GM) After Total Hip Arthroplasty (THA)

Trial Profile

Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Regeneration of Injured Gluteal Musculature (GM) After Total Hip Arthroplasty (THA)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emiplacel (Primary)
  • Indications Muscle injury
  • Focus Therapeutic Use
  • Sponsors Pluristem Therapeutics
  • Most Recent Events

    • 10 Oct 2018 According to a Pluristem Therapeutics media release, Dr. Tobias Winkler, at the Berlin-Brandenburg Center for Regenerative Therapies is principal investigator of this study.
    • 10 Oct 2018 According to a Pluristem Therapeutics media release, results were published in the peer-reviewed Journal of Cachexia, Sarcopenia and Muscle.
    • 18 Sep 2015 Status changed from active, no longer recruiting to completed as reported in ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top